DPP IV inhibitors show promise for new drugs.

PPD and its partner Syrrx have filed an investigational new drug application for a treatment of type II diabetes with the Food and Drug Administration.
The companies said the newest, known as SYR619, has shown promise in early clinical studies. Both proposed drugs are based on so-called DPP IV inhibitors but each relies on separate chemical classes. DPP is related to regulation of insulin levels.
The companies said their research also has the potential to treat obesity, high cholesterol, and other metabolic problems.